相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PLX4032: does it keep its promise for metastatic melanoma treatment?
Elisabeth Livingstone et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects Systematic Review and Meta-regression Analysis
Dirk Bassler et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
Konstantin J. Dedes et al.
EUROPEAN JOURNAL OF CANCER (2009)
Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial
Apostolia-Maria Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?
Franklin G. Miller et al.
CLINICAL TRIALS (2008)
Randomized trials in oncology stopped early for benefit
Ryan A. Wilcox et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bench to bedside - Mapping the moral terrain of clinical research
Steven Joffe et al.
HASTINGS CENTER REPORT (2008)
Treatments for metastatic melanoma: Synthesis of evidence from randomized trials
Philip Lui et al.
CANCER TREATMENT REVIEWS (2007)
Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy
Patricia A. Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis
Kent R. Johnson et al.
LANCET ONCOLOGY (2006)
Randomized trials stopped early for benefit -: A systematic review
VM Montori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
P Bruzzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Principles of early stopping of randomized trials for efficacy: A critique of equipoise and an alternative nonexploitation ethical framework
D Buchanan et al.
KENNEDY INSTITUTE OF ETHICS JOURNAL (2005)
Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?
TD Shanafelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Estrogen plus progestin and the risk of coronary heart disease
JE Manson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
JE Rossouw et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
A controlled trial of arthroscopic surgery for osteoarthritis of the knee
JB Moseley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
M Buyse et al.
LANCET (2000)
What makes clinical research ethical?
EJ Emanuel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
EA Stadtmauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
